Nicole Junkermann navigates the uncharted territories of innovation with the precision of a master explorer. Through NJF Holdings, she's developed a proprietary "disruption compass" that identifies technological convergence points years before mainstream recognition. Her current obsession? Quantum biotechnology startups merging AI with molecular engineering—including a revolutionary protein-folding platform that could slash drug development timelines by 80%.

The Swiss-German investor's "Future Density Index" evaluates startups through three lenses: scientific viability, market potential, and societal impact. This framework recently led her to back Europe's most promising fusion energy venture and a neural interface company developing thought-controlled prosthetics. Junkermann's unique edge comes from her "Tech Scout Network"—a global web of scientists and engineers who alert her to breakthroughs still in lab phases.

Beyond investments, Nicole operates a "Deep Tech Foundry" that accelerates scientific discoveries to market readiness. Her upcoming "Frontier Futures" symposium will unveil a radical new model for commercializing university research that could redefine tech transfer economics.

With her newest €500M fund targeting epigenetic programming and carbon capture nanotechnology, Junkermann isn't just mapping the future—she's actively shaping its terrain.

More informations about Nicole Junkermann